Los Angeles Eye Group Pioneers Non-Surgical JETREA Treatment for Vitreomacular Adhesion

After the FDA approved the use of JETREA injections to treat vitreomacular adhesion last October, Los Angeles-based Retina-Vitreous Associates Medical Group claims it is the first on the West Coast to use the drug to treat VMA patients non-surgically.

Advertisement

JETREA (ocriplasmin) is a proteolytic enzyme that is injected into the eye in a single dose to break down proteins that adhere the vitreous to the macula.

More Articles on Ophthalmology:

Chesapeake Eye Care & Laser Center in Maryland Now Offers LenSx Cataract Surgery
Ophthalmologist’s Office Raided Amid Sex, Fraud Scandal
President Obama Presents Innovation Award to Lasik Inventor

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.